Codiak BioSciences to Present at the Goldman Sachs 42nd Annual Global Healthcare Virtual Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Codiak BioSciences, a clinical-stage biopharmaceutical company focused on exosome-based therapeutics, will have its CEO, Douglas E. Williams, Ph.D., participate in the Goldman Sachs 42nd Annual Global Healthcare Virtual Conference.
The event is scheduled for June 10 at 3:00 PM ET. A live webcast will be available on the company’s website, with an archived replay accessible for 30 days post-event.
Codiak leverages its proprietary engEx™ Platform to develop engineered exosomes aimed at treating various diseases, including oncology and neurology.
Details
News Market Reaction – CDAK
The recorded move for CDAK in the trading session of this news was -1.11%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that its President and Chief Executive Officer, Douglas E. Williams, Ph.D., will participate in a virtual fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference. Details are as follows:
Goldman Sachs 42nd Annual Global Healthcare Virtual Conference
Date: Thursday, June 10
Time: 3:00 PM ET
A live webcast of the virtual fireside chat will be available on the Investors & Media section of the Codiak website at www.codiakbio.com. An archived replay will be available for approximately 30 days following the fireside chat.
About Codiak BioSciences
Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx™ Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.